Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Inventors

CICIC, Dragan

Assignees

Actinium Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11364235-B2

Patent

Publication Date

2022-06-21

Expiration Date


Abstract

This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

Core Innovation

The invention relates to treating a mammalian subject afflicted with acute myeloid leukemia by administering a BCL-2 inhibitor in conjunction with an anti-CD33 antibody labeled with an alpha-emitting isotope, where the combined administration is therapeutically effective. In specific embodiments, the BCL-2 inhibitor is venetoclax and the anti-CD33 antibody is HuM195 labeled with 225Ac. The document further describes inducing the death of acute myeloid leukemia cells by contacting the cells with the BCL-2 inhibitor together with the alpha-emitting, cancer-targeting anti-CD33 radioimmunotherapeutic agent.

The document frames a problem associated with venetoclax and beta radiation, including limitations such as tumor hypoxia and dose feasibility. It provides a rationale that alpha-emitting radioconjugates can more effectively induce apoptosis in targeted cancer cells, and states that alpha particles can lead to DNA double-strand breaks and caspase activation. In this context, the combination therapy is presented as a way to address limitations of existing approaches used with venetoclax and other radiation modalities.

The described compositions and approaches include alpha-emitting isotopes such as 225Ac, 213Bi, and 213Po in connection with an anti-CD33 antibody, including 225Ac-HuM195 (225Ac-lintuzumab) as a preferred example. The document also describes a pre-targeted radioimmunotherapy (PRIT) variant framework and includes general definitions. Extensive dosing regimen scenarios for AML with venetoclax plus 225Ac-HuM195 are described, including embodiments that use sub-saturating or less-than-label dosing and conditions characterized by low peripheral blast burden.

Claims Coverage

The independent claims cover four complementary aspects: treating a mammalian subject afflicted with acute myeloid leukemia using a BCL-2 inhibitor and an alpha-emitting anti-CD33 radioimmunotherapeutic, treating a human subject afflicted with acute myeloid leukemia using venetoclax with 225Ac-labeled HuM195, and inducing death of acute myeloid leukemia cells by contacting them with the same combinations. Across these independent claims, the document emphasizes concurrent combination administration or contacting with effective amounts.

Combination therapy using a BCL-2 inhibitor with an alpha-emitting anti-CD33 antibody

Administering to a mammalian subject afflicted with acute myeloid leukemia a BCL-2 inhibitor in conjunction with an anti-CD33 antibody labeled with an alpha-emitting isotope, wherein the combined administration is therapeutically effective.

Venetoclax with 225Ac-labeled HuM195 for treating human AML

Administering to a human subject afflicted with acute myeloid leukemia venetoclax in conjunction with 225Ac-labeled HuM195, wherein the amounts of venetoclax and 225Ac-labeled HuM195, when administered in conjunction with one another, are therapeutically effective.

Inducing AML cell death by contacting with BCL-2 inhibitor plus alpha-emitting anti-CD33 antibody

Inducing the death of an acute myeloid leukemia cell by contacting the cell with a BCL-2 inhibitor in conjunction with an anti-CD33 antibody labeled with an alpha-emitting isotope, wherein the amounts concurrently contacted are effective to induce the cell's death.

Inducing AML cell death by contacting with venetoclax plus 225Ac-labeled HuM195

Inducing the death of an acute myeloid leukemic cell by contacting the cell with venetoclax in conjunction with 225Ac-labeled HuM195, wherein the amounts of venetoclax and 225Ac-labeled HuM195, when concurrently contacted with the cell, are effective to induce the cell's death.

Across the independent claims, the inventive coverage centers on therapeutically effective combination use of a BCL-2 inhibitor and an anti-CD33 antibody labeled with an alpha-emitting isotope, with specific embodiments for venetoclax and 225Ac-labeled HuM195, and parallel coverage for inducing death of acute myeloid leukemia cells through concurrent contacting with these components.

Stated Advantages

Alpha emitters can more effectively induce apoptosis in targeted cancer cells.

Alpha particles can cause DNA double-strand breaks and caspase activation in targeted cells.

The combination is presented as addressing limitations of venetoclax and beta radiation, including tumor hypoxia and dose feasibility.

Documented Applications

Treating a mammalian subject afflicted with acute myeloid leukemia using a BCL-2 inhibitor in conjunction with an alpha-emitting, anti-CD33 antibody radioimmunotherapeutic.

Treating a human subject afflicted with acute myeloid leukemia using venetoclax in conjunction with 225Ac-labeled HuM195.

Inducing the death of an acute myeloid leukemia cell by contacting it with a BCL-2 inhibitor together with an alpha-emitting anti-CD33 antibody radioimmunotherapeutic.

Inducing the death of an acute myeloid leukemic cell by contacting it with venetoclax together with 225Ac-labeled HuM195.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.